Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 5
Submit an article Journal homepage
1,132
Views
2
CrossRef citations to date
0
Altmetric
Coronavirus – Letters

COVID-19 vaccination rate and side effects in CVID patients over the age of 12

Öner Özdemira Division of Allergy and Immunology, Department of Pediatrics, Research and Training Hospital of Sakarya University Medical Faculty, Adapazarı, TürkiyeCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5338-9561View further author information
ORCID Icon &
Ümmügülsüm Dikicib Division of Pediatric Allergy and Immunology, Research and Training Hospital of Sakarya University Medical Faculty, Adapazarı, TürkiyeORCID Iconhttps://orcid.org/0000-0002-7435-1108View further author information
ORCID Icon
Article: 2068337 | Received 01 Apr 2022, Accepted 15 Apr 2022, Published online: 28 Apr 2022

References

  • Dhama K, Sharun K, Tiwari R, Dhawan M, Emran TB, Rabaan AA, Alhumaid S. COVID-19 vaccine hesitancy - reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic. Hum Vacin Immunother. 2021;17(10):3495–2. doi:10.1080/21645515.2021.1926183.
  • Gerber JS, Offit PA. COVID-19 vaccines for children. Science. 2021;374(6570):913. doi:10.1126/science.abn2566.
  • Yigit M, Ozkaya-Parlakay A, Senel E. Evaluation of COVID-19 vaccine refusal in parents. Pediatr Infect Dis J. 2021;40(4):e134–e136. doi:10.1097/INF.0000000000003042.
  • Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, Ferrajolo C, Moretti U, Poluzzi E, Raschi E, et al. COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergyor prior SARS-CoV-2 infection: overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety. Drug Saf. 2021;44(12):1247–69. doi:10.1007/s40264-021-01131-6.
  • Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, Söderdahl G, Österborg A, Smith CIE, Wullimann D, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine. 2021;74:103705. doi:10.1016/j.ebiom.2021.103705.
  • Ameratunga R, Woon S-T, Steele R, Lehnert K, Leung E, Edwards ESJ, Brooks AES. Common variable immunodeficiency disorders as a model for assessing COVID-19 vaccine responses in immunocompromised patients. Front Immunol. 2022;12:798389. doi:10.3389/fimmu.2021.798389.
  • Amodio D, Ruggiero A, Sgrulletti M, Pighi C, Cotugno N, Medri C, Morrocchi E, Colagrossi L, Russo C, Zaffina S, et al. Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies. Front Immunol. 2021;12:727850. doi:10.3389/fimmu.2021.727850.
  • Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, Tay SH, Teo CB, Tan BKJ, Chan YH, et al. Efficacy of Covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632. doi:10.1136/bmj-2021-068632.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.